| scholarly article | Q13442814 |
| P50 | author | Dena Grayson | Q20758232 |
| Donald F Smee | Q66732853 | ||
| John D Morrey | Q66760143 | ||
| P2093 | author name string | Justin G Julander | |
| William P Sheridan | |||
| Shanta Bantia | |||
| Yarlagadda S Babu | |||
| Pravin Kotian | |||
| Brian R Taubenheim | |||
| P2860 | cites work | Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model | Q27478175 |
| Activity of T-1106 in a Hamster Model of Yellow Fever Virus Infection | Q27480272 | ||
| In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus Infections | Q27481401 | ||
| Activity of T-705 in a Hamster Model of Yellow Fever Virus Infection in Comparison with That of a Chemically Related Compound, T-1106 | Q27487527 | ||
| Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus) III. Clinical laboratory values. | Q33371482 | ||
| Efficacy of 2'-C-methylcytidine against yellow fever virus in cell culture and in a hamster model | Q33856419 | ||
| Treatment of yellow fever | Q34008580 | ||
| Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. | Q34040052 | ||
| Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease | Q34350325 | ||
| Yellow fever: a disease that has yet to be conquered | Q34557933 | ||
| Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model | Q34933362 | ||
| Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model | Q35141448 | ||
| Experimental therapies for yellow fever | Q36586306 | ||
| The dengue vector Aedes aegypti: what comes next | Q37680253 | ||
| Review of the risks and benefits of yellow fever vaccination including some new analyses | Q38006992 | ||
| Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies | Q39518371 | ||
| Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology | Q39607499 | ||
| Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity | Q40362914 | ||
| Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues | Q40854564 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | yellow fever | Q154874 |
| yellow fever virus | Q836749 | ||
| P304 | page(s) | 6607-6614 | |
| P577 | publication date | 2014-08-25 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model | |
| P478 | volume | 58 |
| Q37415438 | A Novel Benzodiazepine Compound Inhibits Yellow Fever Virus Infection by Specifically Targeting NS4B Protein. |
| Q64359221 | An E460D substitution in the NS5 protein of tick-borne encephalitis virus confers resistance to the inhibitor Galidesivir (BCX4430) and also attenuates the virus for mice |
| Q37077376 | BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease |
| Q29994527 | Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond |
| Q38519881 | Broad-spectrum antiviral agents |
| Q41919714 | Current landscape and future prospects of antiviral drugs derived from microbial products |
| Q38546746 | Development of Small-Molecule Antivirals for Ebola |
| Q30395163 | Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model |
| Q91900265 | Efficient diastereoselective synthesis of a new class of azanucleosides: 2'-homoazanucleosides |
| Q40063157 | Evaluation of cell viability dyes in antiviral assays with RNA viruses that exhibit different cytopathogenic properties |
| Q114704017 | Flavivirus enzymes and their inhibitors |
| Q59359898 | Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters |
| Q33439713 | Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies |
| Q56395905 | Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model |
| Q92471636 | New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections |
| Q47558305 | Nonhuman Primate Models of Zika Virus Infection, Immunity, and Therapeutic Development |
| Q54256710 | Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses. |
| Q29994672 | Offering patients more: how the West Africa Ebola outbreak can shape innovation in therapeutic research for emerging and epidemic infections |
| Q37203877 | Prophylactic Efficacy of Quercetin 3-β-O-d-Glucoside against Ebola Virus Infection |
| Q47558337 | Small-Animal Models of Zika Virus |
| Q52323442 | The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. |
| Q57168259 | What Does the Future Hold for Yellow Fever Virus? (II) |
Search more.